12th November 2015
Nuformix is pleased to announce it has received the grant of its NXP001 patent for China. Nuformix is pursuing global patent coverage for its NXP001 asset, which offers multiple options for future development. Nuformix Chief Executive Officer, Dr Dan Gooding, said: “Nuformix has already had patents grant in China for its proprietary cocrystal drugs forms. However, NXP001 is a critical asset for Nuformix, so we’re glad to see consistency from the State Intellectual Property Office in its award of this latest Nuformix patent. The Chinese market represents a stand-out opportunity for this particular asset.”